Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The hepatoprotective antioxidant bioflavonoid cianidanol has beneficial therapeutic and immunomodulatory effects in chronic hepatitis. Its action on natural killer (NK) cell activity has not yet been studied in hepatitis B virus (HBV) infection. In the present study, the in vitro and in vivo effects of the drug on NK cell activity have been determined in six patients with chronic HBV hepatitis and in ten healthy control subjects. Two methods were used: an enzyme release assay and a cytotoxicity test based on the assessment of endogenous alkaline phosphatase activity of the target cells. The in vitro effect of the drug was assessed using cianidanol at 10(-6), 10(-5) and 10(-4) M concentrations. For in vivo studies, HBV hepatitis patients were treated with cianidanol at a daily dose of 3.0 g cianidanol for seven days and were investigated before and after the treatment. Chronic HBV hepatitis patients showed a moderate decrease in NK cell activity compared to the controls, but after the cianidanol therapy their NK cell activity significantly rose to 68.0% +/- 9.5% (p less than 0.01). Cianidanol in vitro inhibited the NK cell activity both in hepatitis and healthy groups when using K-562 target cells and the lactic acid dehydrogenase enzyme release assay, but did not influence or even slightly enhance the NK activity when human embryonic fibroblast cells and alkaline phosphatase assay were used for the test. After the 7-day in vivo treatment, the in vitro inhibitory action of the drug was diminished or absent.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Effect of cianidanol on natural killer cell activity in patients with chronic B virus hepatitis. 359 73

This study was designed to investigate the effect of the natural bioflavonoid compound cianidanol on the blood lipid peroxide status of patients with chronic hepatitis. Nine patients had chronic active liver disease--seven of them hepatitis B virus-positive--and five had chronic alcoholic hepatitis. Besides some biochemical liver function tests (serum bilirubin, aminotransferases and gamma-glutamyl transferase), the changes in the serum level of malondialdehyde (a thiobarbituric acid reactive substance) as one of the end-products of lipid peroxidation, as well as the quantity/or activity of enzymes controlling peroxidation (superoxide dismutase (SOD), glutathione peroxidase and catalase) were measured. In addition, the serum level of the natural antioxidant vitamin E was followed-up. Cianidanol treatment (at a dose of 3.0 g/day for one month and of 1.5 g/day for two months) resulted in a slight improvement in aminotransferases and a significant fall (normalization) of high serum malondialdehyde level. After a marked transient increase, serum SOD content decreased while glutathione peroxidase and catalase activities as well as the vitamin E blood level increased during the treatment. Results suggest that (cianidanol in vivo inhibits lipid peroxidation and influences antioxidant enzyme systems and vitamin E in the blood of patients with chronic hepatitis.
 ...
PMID:Effects of cianidanol on the blood lipid peroxide status in patients with chronic hepatitis. 409 18